TP53 and breast carcinoma: Similar results were observed in breast cancer cells, where 25-OCH3-PPD downregulated MDM2 expression at both transcriptional and posttranslational levels in a time- and dose-dependent manner, irrespective of p53 status (Wang et al., 2012[240]).